Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial.

DeZure AD, Coates EE, Hu Z, Yamshchikov GV, Zephir KL, Enama ME, Plummer SH, Gordon IJ, Kaltovich F, Andrews S, McDermott A, Crank MC, Koup RA, Schwartz RM, Bailer RT, Sun X, Mascola JR, Tumpey TM, Graham BS, Ledgerwood JE.

NPJ Vaccines. 2017 Jun 1;2:15. doi: 10.1038/s41541-017-0016-6. eCollection 2017.

2.

Beyond attachment: Roles of DC-SIGN in dengue virus infection.

Liu P, Ridilla M, Patel P, Betts L, Gallichotte E, Shahidi L, Thompson NL, Jacobson K.

Traffic. 2017 Apr;18(4):218-231. doi: 10.1111/tra.12469. Epub 2017 Feb 28.

3.

Dendritic cells: microbial clearance via autophagy and potential immunobiological consequences for periodontal disease.

El-Awady AR, Arce RM, Cutler CW.

Periodontol 2000. 2015 Oct;69(1):160-80. doi: 10.1111/prd.12096. Review.

4.

Innate receptors and cellular defense against pulmonary infections.

Werner JL, Steele C.

J Immunol. 2014 Oct 15;193(8):3842-50. doi: 10.4049/jimmunol.1400978. Review.

5.

Molecular pathology of emerging coronavirus infections.

Gralinski LE, Baric RS.

J Pathol. 2015 Jan;235(2):185-95. doi: 10.1002/path.4454. Review.

6.

Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness.

Sui J, Deming M, Rockx B, Liddington RC, Zhu QK, Baric RS, Marasco WA.

J Virol. 2014 Dec;88(23):13769-80. doi: 10.1128/JVI.02232-14. Epub 2014 Sep 17.

7.

Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial.

Sarwar UN, Costner P, Enama ME, Berkowitz N, Hu Z, Hendel CS, Sitar S, Plummer S, Mulangu S, Bailer RT, Koup RA, Mascola JR, Nabel GJ, Sullivan NJ, Graham BS, Ledgerwood JE; VRC 206 Study Team.

J Infect Dis. 2015 Feb 15;211(4):549-57. doi: 10.1093/infdis/jiu511. Epub 2014 Sep 14.

8.

Antiviral drugs specific for coronaviruses in preclinical development.

Adedeji AO, Sarafianos SG.

Curr Opin Virol. 2014 Oct;8:45-53. doi: 10.1016/j.coviro.2014.06.002. Epub 2014 Jul 2. Review.

9.

Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus.

Yip MS, Leung NH, Cheung CY, Li PH, Lee HH, Daëron M, Peiris JS, Bruzzone R, Jaume M.

Virol J. 2014 May 6;11:82. doi: 10.1186/1743-422X-11-82.

10.
11.

Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research.

Simmons G, Zmora P, Gierer S, Heurich A, Pöhlmann S.

Antiviral Res. 2013 Dec;100(3):605-14. doi: 10.1016/j.antiviral.2013.09.028. Epub 2013 Oct 8. Review.

12.

A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV.

Zhao G, Du L, Ma C, Li Y, Li L, Poon VK, Wang L, Yu F, Zheng BJ, Jiang S, Zhou Y.

Virol J. 2013 Aug 26;10:266. doi: 10.1186/1743-422X-10-266.

13.

Receptor-binding domain as a target for developing SARS vaccines.

Zhu X, Liu Q, Du L, Lu L, Jiang S.

J Thorac Dis. 2013 Aug;5 Suppl 2:S142-8. doi: 10.3978/j.issn.2072-1439.2013.06.06.

14.

Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms.

Adedeji AO, Severson W, Jonsson C, Singh K, Weiss SR, Sarafianos SG.

J Virol. 2013 Jul;87(14):8017-28. doi: 10.1128/JVI.00998-13. Epub 2013 May 15.

15.

Binding of DC-SIGN to the hemagglutinin of influenza A viruses supports virus replication in DC-SIGN expressing cells.

Hillaire ML, Nieuwkoop NJ, Boon AC, de Mutsert G, Vogelzang-van Trierum SE, Fouchier RA, Osterhaus AD, Rimmelzwaan GF.

PLoS One. 2013;8(2):e56164. doi: 10.1371/journal.pone.0056164. Epub 2013 Feb 12.

16.

Development of a pseudotyped-lentiviral-vector-based neutralization assay for chikungunya virus infection.

Kishishita N, Takeda N, Anuegoonpipat A, Anantapreecha S.

J Clin Microbiol. 2013 May;51(5):1389-95. doi: 10.1128/JCM.03109-12. Epub 2013 Feb 13.

17.

Development of novel entry inhibitors targeting emerging viruses.

Zhou Y, Simmons G.

Expert Rev Anti Infect Ther. 2012 Oct;10(10):1129-38. doi: 10.1586/eri.12.104. Review.

18.

Monitoring of S protein maturation in the endoplasmic reticulum by calnexin is important for the infectivity of severe acute respiratory syndrome coronavirus.

Fukushi M, Yoshinaka Y, Matsuoka Y, Hatakeyama S, Ishizaka Y, Kirikae T, Sasazuki T, Miyoshi-Akiyama T.

J Virol. 2012 Nov;86(21):11745-53. doi: 10.1128/JVI.01250-12. Epub 2012 Aug 22.

19.

HIV: cell binding and entry.

Wilen CB, Tilton JC, Doms RW.

Cold Spring Harb Perspect Med. 2012 Aug 1;2(8). pii: a006866. doi: 10.1101/cshperspect.a006866. Review.

20.

Mechanisms of coronavirus cell entry mediated by the viral spike protein.

Belouzard S, Millet JK, Licitra BN, Whittaker GR.

Viruses. 2012 Jun;4(6):1011-33. doi: 10.3390/v4061011. Epub 2012 Jun 20. Review.

Supplemental Content

Support Center